deltatrials
Terminated PHASE1/PHASE2 NCT01755858

Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery

A Phase 2a, Placebo-controlled Trial to Evaluate the Impact of Intravenous Bendavia™ on Ischemia Reperfusion Injury in Atherosclerotic Renal Artery Stenosis in Patients Undergoing Percutaneous Transluminal Angioplasty of the Renal Artery

Sponsor: Stealth BioTherapeutics Inc.

Conditions Hypertension, Renovascular Ischemia Reperfusion Injury Renal Artery Obstruction
Interventions Bendavia Placebo
Updated 7 times since 2017 Last updated: Aug 10, 2020 Started: Dec 31, 2012 Primary completion: Dec 31, 2015 Completion: May 31, 2016

This PHASE1/PHASE2 trial investigates Hypertension, Renovascular and Ischemia Reperfusion Injury and is currently terminated or withdrawn. Stealth BioTherapeutics Inc. leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Sep 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  5. Jun 2018 — Sep 2020 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1_PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1_PHASE2

    First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Stealth BioTherapeutics Inc.
Data source: Stealth BioTherapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Rochester, United States